Breaking News, Collaborations & Alliances

Epsilogen & Lonza Successfully Complete Large-Scale GMP Manufacturing of MOv18

New IgE antibody drug candidate represents a powerful alternative to more commonly used IgG antibodies.

Author Image

By: Charlie Sternberg

Associate Editor

Epsilogen, a developer of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have successfully completed Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate—including process development and cGMP manufacturing of this complex molecule for clinical supply in less than ten months at Lonza’s Slough (UK) site.   IgE antibodies represent p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters